Gynecology
New studies show embolization better treatment option for uterine fibroids
Published in OBGYN and Reproduction Week, November 6th, 2006
The Dutch study (EMMY trial, Prof Reekers, Amsterdam) and the Scottish study (REST trial, Dr Moss, Glasgow) were performed independently. The REST study shows a similar quality of life for both groups one year after the procedure (embolization versus surgery). The EMMY study shows that this result was also maintained after a 2 year follow-up period.
Surgical treatments like hysterectomy could be avoided in more than 80% of all women after a...
Want to see the full article?
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of OBGYN and Reproduction Week
More Articles from OBGYN and Reproduction Week
- Cervical Cancer
Hypoxic cervical cancer cells sway treatment outcomes - Obstetrics
Decidual natural killer cells govern key functions at the human fetal-maternal interface - Obstetrics
In utero treatments for certain birth defects may be on the horizon - Ovarian Cancer
Genetic tests to identify ovarian cancer have little clinical value - Bladder Cancer Therapy
Researchers at National Institutes of Health, Division of Cancer Epidemiology and Genetics release new data on bladder cancer therapy - Breast Cancer Risk Factors
Reports outline breast cancer risk factors research from George Washington University, Department of Epidemiology and Biostatistics - More from this issue of OBGYN and Reproduction Week
NewsRx is Social
Follow us on your favorite social network by clicking on a button below:
Top Medical Newsletters
Awards
Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005
Facts & Stats
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.
- Google 2010 PageRank: #2 Among Top Health News and Media Publications
- Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
- Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
- Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry
